secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0001193125-23-036988
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx expects Q4 and FY 2022 revenue to meaningfully exceed consensus on higher RELYVRIO demand
--------------------------------------------------------------------------------

- Insurers covering ~25% of U.S. covered lives have published policies; nearly all provide broad access to RELYVRIO.
- EU decision on AMX0035 marketing authorization for ALS expected first half 2023; CHMP SAG meeting this month.
- Phase 3 PHOENIX trial (664 participants) completed enrollment; topline results anticipated mid-2024.
- Starting Feb 19, pharmacy network data will no longer flow to third-party data vendors (closed network model).
- Company provides update at SVB Securities conference; Q4 and FY 2022 financial results call in early March 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312523036988/0001193125-23-036988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312523036988/d461886d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-036988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer